Note:This article does not constitute any investment opinions or suggestions; please refer to official/company announcements for accuracy.This article only introduces drugs related to medical health, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.
PharmaCircleMonitoring Shows: Epis NexLab was founded on November 11, 2025, as a wholly-owned subsidiary of Korean giant Samsung/Samsung Epis Holdings. It is committed to driving innovative development through the research and development of next-generation biotechnology platforms. Epis NexLab transforms highly scalable peptide-related technologies into a drug discovery platform, focusing on exploring innovative therapeutic modalities and developing multiple candidate treatments for various diseases.
In the medium to long term, the company will focus on converting peptide-related technologies intoDevelopment Platform. Build a differentiated technology platform based on peptides (amino acid compounds) with drug delivery and function-enhancing characteristics, and carry out candidate new drug discovery work for major diseases such as obesity, diabetes, and cancer. (The image above shows the recently presented business model BP.)
At the recent 2026 JPM conference, Kyung-Ah Kim, President and CEO of Samsung Bioepis Holdings, stated: "2026 is a landmark year for us as we enter a new chapter in our company’s growth. We are announcing the addition of six new candidate drugs to our biosimilar pipeline, including vedolizumab and dupilumab. We are steadily progressing toward our goal of having a pipeline that includes 20 biosimilars by 2030. Additionally, the first novel therapeutic candidate drug independently developed by Samsung Bioepis has received Investigational New Drug (IND) approval, and we plan to advance the related clinical program this year. Beyond biosimilars, we will further expand our product portfolio and continue investing in the research and development of Antibody-Drug Conjugates (ADCs), leveraging our innovative R&D platform to provide viable treatment options for patients with unmet medical needs."PharmaCircleData show: currentlySBE303 is the first novel ADC developed by Samsung Bioepis, targeting Nectin-4.。This adhesion protein is specifically expressed in various tumor cells such as urothelial carcinoma, lung cancer, and breast cancer. It has already entered Phase I clinical trials in the United States. Aiming to demonstrate deep cooperation with other multinational pharmaceutical companies in the future.
References:
PharmaCircle Data;
Moxie Pharma pharma.bcpmdata.com (formerly Pharma Data Cloud);
https://www.samsungepisholdings.com/；
https://www.samsungepisholdings.com/en/about/about03.do；
https://www.businesswire.com/news/home/20260114048753/zh-HK；
https://www.businesswire.com/news/home/20251020320860/en/Samsung-Bioepis-And-Phrontline-Announce-a-Global-Strategic-Partnership-to-Advance-Best-in-Class-Antibody-Drug-Conjugate-Therapeutics-for-Solid-Tumors；Etc.
